Danaher(US:DHR) ZACKSยท2025-04-21 15:20Core Viewpoint - Danaher Corporation is expected to report a decline in both revenue and earnings for the first quarter of 2025, with revenues estimated at $5.56 billion, a decrease of 4.2% year-over-year, and earnings per share projected at $1.62, down 15.6% from the previous year [1]. Group 1: Financial Estimates - The Zacks Consensus Estimate for revenues is $5.56 billion, indicating a 4.2% decrease from the same quarter last year [1]. - The consensus estimate for earnings is $1.62 per share, reflecting a 15.6% decline compared to the year-ago quarter [1]. - In the last reported quarter, the company's bottom line missed the Zacks Consensus Estimate by 1.4%, but it had an average earnings surprise of 7.4% over the last four quarters [2]. Group 2: Segment Performance - The Diagnostics segment is expected to see a revenue decrease of 7% year-over-year to $2.35 billion, despite strength in molecular diagnostics driven by increased testing [3]. - The Life Sciences segment is facing challenges due to sluggish demand in pharma and biotech markets in China, leading to a decline in sales across various instrument businesses [4]. - The genomics consumables business is also expected to decline by 6.9% year-over-year to $1.62 billion due to weak sales in gene reading and protein product lines [5]. - Conversely, the Biotechnology segment is projected to grow by 4.1% year-over-year to $1.59 billion, supported by strong demand for bioprocessing and consumables [6]. Group 3: Strategic Developments - Danaher acquired Abcam plc in December 2023, enhancing its Life Sciences segment with a strong portfolio of protein consumables [7]. - The company is experiencing rising costs of sales, which may negatively impact profitability, alongside foreign currency headwinds due to its international market exposure [8]. Group 4: Earnings Prediction - The company has an Earnings ESP of +0.33%, with the Most Accurate Estimate at $1.63 per share, suggesting a potential earnings beat [10].